What is PROCEPT BioRobotics Debt-to-Equity?
PROCEPT BioRobotics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.7 Mil. PROCEPT BioRobotics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $79.7 Mil. PROCEPT BioRobotics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $264.0 Mil.
PROCEPT BioRobotics's debt to equity for the quarter that ended in Mar. 2024 was 0.31.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PROCEPT BioRobotics's Debt-to-Equity or its related term are showing as below:
PRCT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.3 Med: 0.25 Max: 0.52
Current: 0.31
During the past 5 years, the highest Debt-to-Equity Ratio of PROCEPT BioRobotics was 0.52. The lowest was -0.30. And the median was 0.25.
PROCEPT BioRobotics Debt-to-Equity Historical Data
The historical data trend for PROCEPT BioRobotics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics Debt-to-Equity Chart
|
PROCEPT BioRobotics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
-0.16 |
-0.30 |
0.20 |
0.39 |
0.28 |
|
PROCEPT BioRobotics Quarterly Data
|
|
Dec19 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
0.46 |
0.52 |
0.27 |
0.28 |
0.31 |
Competitive Comparison of PROCEPT BioRobotics's Debt-to-Equity
For the Medical Devices subindustry, PROCEPT BioRobotics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Debt-to-Equity falls into.
PROCEPT BioRobotics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
PROCEPT BioRobotics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
PROCEPT BioRobotics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description
Traded in Other Exchanges
N/A
Address
900 Island Drive, Redwood, CA, USA, 94065
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Executives
| Alaleh Nouri |
officer: SVP, GEN COUNSEL, CORP. SEC. |
1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089 |
| Kevin Waters |
officer: Senior VP, CFO |
1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089 |
| Frederic H Moll |
director |
C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086 |
| Wood Morgan Colby |
director |
C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065 |
| Reza Zadno |
director, officer: President, CEO |
2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025 |
| Hisham Shiblaq |
officer: SVP, Commercial Operations |
C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065 |
| Thomas M Krummel |
director |
C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118 |
| Viking Global Investors Lp |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Opportunities Parent Gp Llc |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Dragsa 88 Llc |
10 percent owner |
55 RAILROAD AVE, GREENWICH CT 06830 |
| Rose Sharon Shabet |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Opportunities Illiquid Investments Sub-master Lp |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| Viking Global Opportunities Gp Llc |
10 percent owner |
55 RAILROAD AVENUE, GREENWICH CT 06830 |
| Viking Global Opportunities Portfolio Gp Llc |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
| David C. Ott |
10 percent owner |
600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
PROCEPT BioRobotics (PROCEPT BioRobotics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRCT has been successfully added to your